Profile cover photo
Profile photo
Sciformix
11 followers
11 followers
About
Sciformix's posts

Post has attachment
Suhasini Sharma, Director of Medical Affairs at Sciformix writes on the significant growth of pharmaceutical medical writing in India in the last couple of decades. Read the full article here. 

Post has attachment
Dr. Chitra Lele, Chief Scientific Officer at Sciformix writes on the history and evolution of statistics in the era of evidence based medicine with a focus on the Indian perspective of this growth of statistics as a discipline for clinical research.

Post has attachment
Michael Zelasky, Principal - Global Biometrics at Sciformix writes on the FDA draft guidance for IND Safety Reporting released in December 2015 and how aggregate analysis in an important component of SUSARs reporting. He also stresses on the fact that care must be taken to ensure the proper statistical methods are used. Read the full post here. 

Post has attachment
We kick off 2017 with our first blog post of the year. Sanyogita Rane, Project Manager at Sciformix writes on how the new ICH E19 guideline will prove to be another stride toward harmonizing and optimizing the collection of safety data during late stage pre-market and post-approval clinical investigations of new drugs and new indications for approved drugs. Read the full post here.

Post has attachment

Manish Soman, President and CEO, Sciformix Corporation recently sat down with Dun and Bradstreet to discuss the company's genesis, it's journey so far, the services it offers and its growth strategy as it moves into new markets and service areas. Click here to read the full interview. 

Post has attachment
Dr. Chitra Lele, Chief Scientific Officer at Sciformix writes in Contract Pharma on importance of the 3E principle when considering and selecting an outsourcing partner, specifically in the context of outsourcing knowledge-based functions in drug development and post-marketing in the areas of safety and risk management, statistics and programming, scientific writing and regulatory affairs.

Post has attachment
Suhasini Sharma, Director of Medical Affairs at Sciformix Corporation explains how effective medical communication can pave the road to success in emerging markets. Read it here.

Post has attachment
Bindu Narang, Director - Safety Writing and Regulatory Affairs at Sciformix writes on the FDA’s Proposed Generic-Drug Labeling Rule and how, when it is passed, in 2017 will lead to generic drug companies needing documented processes for safety tracking and label updates. 

Post has attachment
Sciformix is proud to announce that it has been awarded the 'Best Safety & Risk Management Company' in the 2016 International Life Sciences Awards organized by GHP Magazine. For more information check out the link below.

Post has attachment
Bindu Narang, Director - Safety Writing and Regulatory Affairs at Sciformix considers the impact of proposed US FDA labeling regulations on the generic drugs sector.
Wait while more posts are being loaded